Rejuvel Bio-Sciences (NUUU) 10-Q 16 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 16, 2015
Document And Entity Information
Entity Registrant Name	Rejuvel Bio-Sciences, Inc.
Entity Central Index Key	1,481,427
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		51,841,723
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,015

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 877	$ 39,501
Accounts receivable	304	0
Inventories	34,826	4,831
Deposits	7,000	7,000
Other current assets	45,890	1,722
Total current assets	88,897	53,053
Intangible assets, net	14,171	15,859
Machinery and equipment, net	27,641	32,092
Other Assets
Security deposits	3,724	3,724
Total assets	134,433	104,728
Current Liabilities
Accounts payable and accrued expenses	600,757	458,783
Advances from affiliate	276,156	270,747
Loan from affiliate	157,068	157,068
Line of Credit	10,000	0
Convertible debentures (net of debt discount of $135,687 and $0 respectively)	189,313	0
Other current liabilities	502	2,713
Derivative liability	467,865	48,851
Total current liabilities	1,701,661	938,162
Long-term Liabilities
Convertible debentures (net of debt discount of $79,726 and $0, respectively)	5,274	0
Total long-term liabilities	5,274	0
Total liabilities	1,706,935	938,162
Shareholders' deficit
Preferred stock, par value, $0.001 per share, 50,000,000 shares authorized, none issued or outstanding	0	0
Common stock, par value $0.001 par value, 300,000,000 shares authorized, 50,813,093 and 50,138,493 shares issued and outstanding at December 31, 2014 and December 31, 2013, respectively.	50,896	50,138
Additional paid in capital	1,734,697	1,274,202
Accumulated deficit	(3,358,095)	(2,157,774)
Total shareholders' deficit	(1,572,502)	(833,434)
Total liabilities and shareholders' deficit	$ 134,433	$ 104,728

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	50,896,385	50,138,493
Common stock, shares outstanding	50,896,385	50,138,493
Discount on convertible debentures	$ 135,687	$ 0

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Revenues	$ 50,408	$ 18,353	$ 156,909	$ 63,677
Cost of revenues	10,232	168	24,279	9,062
Gross profit	40,176	18,185	132,630	54,615
Expenses
General and administrative	275,758	210,777	1,152,868	501,908
Loss From Operation	(235,582)	(192,592)	(1,020,238)	(447,293)
Other income (expense)
Gain on derivative valuation	147,986	629,571	348,614	565,167
Derivative expense	(114,730)	(258,448)	(295,581)	(525,603)
Interest expense	(125,186)	(3,332)	(233,116)	(93,433)
Total other income (expense)	(91,930)	367,791	(180,083)	(53,869)
Net Income (Loss)	$ (327,512)	$ 175,199	$ (1,200,321)	$ (501,162)
Loss per share
Basic	$ (.01)	$ 0	$ (.02)	$ 0
Diluted	$ (.01)	$ 0	$ (.02)	$ 0
Weighted average number of shares
Basic	50,818,525	106,187,007	50,605,915	110,001,487
Diluted	50,818,525	106,245,144	50,605,915	110,001,487

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities
Net loss	$ (1,200,321)	$ (501,162)
Adjustments to reconcile net income to net cash used in operating activities:
Debt issuance cost	23,750	0
Loss (Gain) on derivative valuation	(348,614)	(565,167)
Derivative expense	295,581	525,603
Gain on forgiveness of debts	422,000	0
Amortization of discount on convertible debentures	204,587	75,902
Depreciation and amortization	6,139	4,046
Change in current assets and current liabilities:
Accounts receivable	(304)	0
Inventory	(29,995)	(26,985)
Other current assets	(44,169)	(10,494)
Deposit	0	(3,537)
Accounts payable and accrued expenses	141,974	99,947
Other current liabilities	(2,211)	0
Net cash used in operating activities	(531,583)	(401,847)
Cash flows from investing activities
Purchase of equipment	0	(18,335)
Net cash used in investing activities	0	(18,335)
Cash flows from financing activities
Advances from affiliate, net	86,514	148,458
Repayment of loan from affiliate	(81,105)	(82,448)
Proceeds from issuance of note payable	10,000	0
Proceeds from issuance of convertible debentures	382,750	0
Payment of common stock purchase back	0	(1,000)
Proceeds from issuance of common stock	94,800	538,163
Net cash provided by financing activities	492,959	603,173
Net change in cash and cash equivalents	(38,624)	182,989
Cash and cash equivalents, beginning balance	39,501	4,891
Cash and cash equivalents, ending balance	877	187,880
Supplemental disclosure of cash flow information
Income taxes paid	0	0
Interest paid	0	0
Non-cash transactions affecting Operating, Investing and Financing activities
Issued notes payable for common stock buyback	0	79,667
Original issuance discounts	13,500	0
Debt discount on convertible note	406,500	0
Issuance of common stock for convertible notes converted	$ 22,497	$ 447,325

1. Nature of Operations and Bas

1. Nature of Operations and Basis of Presentation	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
1. Nature of Operations and Basis of Presentation	1. Nature of Operations and Basis of Presentation Nature of Operations Rejuvel Bio-Sciences, Inc. (f/k/a Technology Applications International Corporation) was incorporated on October 14, 2009 under the laws of Florida. Rejuvel Int’l, Inc. and NueEarth, Inc., Rejuvel Bio-Sciences, Inc.’s wholly owned subsidiaries and Rejuvel Bio-Sciences, Inc., collectively, are referred to here-in as the “Company”. The Company is engaged in developing market entry technology products and services into early and mainstream technology products and services. Through our subsidiaries, we are focused on developing and manufacturing a line of technologically advanced skin care products and providing environmental management solutions that use electron particle accelerator technology. Principles of Consolidation The consolidated financial statements include the accounts of Rejuvel Bio-Sciences, Inc., and its wholly owned subsidiaries, Rejuvel Int’l, Inc. and NueEarth, Inc. All significant inter-company accounts and transactions have been eliminated in consolidation. Basis of Presentation and Going Concern Considerations The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2015 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2015. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. The accompanying financial statements have been presented on the basis that it is a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs. The Company’s ability to continue as a going concern is highly dependent upon management’s ability to increase near-term operating cash flows and obtain additional working capital through the issuance of debt and or equity. If the Company is unable to obtain adequate capital, it could be forced to cease operations. These condensed consolidated financial statements present the financial condition, and results of operations and cash flows of the operating companies. Business Risk Since its inception, the Company has been dependent upon the receipt of capital investment to fund its operating activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plans will be successfully executed. The Company’s ability to execute its business plans is dependent on its ability to obtain additional debt and equity financing and achieving a profitable level of operations. There can be no assurance that sufficient financing will be obtained or that we will achieve a profitable level of operations. Basic and Diluted Net Loss per Share The Company computes loss per share in accordance with “ASC-260”, “Earnings per Share” which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. The Company has potential dilutive instruments during the current three month period as there is net income; therefore there is potentially a dilutive share amount of 106,245,144. The Company does not have potential dilutive instruments during the nine month period and comparable periods as there are net losses, and accordingly basic loss and diluted loss per share are the same. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position or results of operations upon adoption.

2. Inventories

2. Inventories	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
2. Inventories	2. Inventories Inventories are stated at the lower of cost or market value. The Company reduces the value of its inventories to market value when the value is believed to be less than the cost of the item. September 30, 2015 December 31, 2014 Raw materials $ - $ - Work-in-process 19,904 - Finished goods 14,922 4,831 Total Inventories $ 34,826 $ 4,831 No reserves for inventory have been deemed necessary at September 30, 2015 and December 31, 2014.

3. Machinery and Equipment

3. Machinery and Equipment	9 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
3. Machinery and Equipment	3. Machinery and Equipment Machinery and equipment are recorded at cost. Expenditures for maintenance and repairs are charged to earnings as incurred whereas additions, renewals and betterments are capitalized. When machinery and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of machinery and equipment is provided using the straight-line method over the assets estimated useful lives of approximately 5 to 7 years. Leasehold improvements, if any, are amortized on a straight-line basis over the term of the lease or the estimated useful lives, whichever is shorter. Machinery and equipment, as of September 30, 2015 and December 31, 2014, consisted of the following: Estimated Useful Lives September 30, 2015 December 31, 2014 Computer Equipment 3 Years $ 3,796 $ 5,980 Machinery and equipment 5 Years 33,192 29,935 Furniture and fixtures 7 Years 13,000 14,073 Accumulated depreciation (22,347) (17,896) $ 27,641 $ 32,092 Depreciation expense for the nine month periods ended September 30, 2015 and 2014 were $4,451 and $3,964, respectively. Depreciation expense for the three month periods ended September 30, 2015 and 2014 were $1,483 and $1,499 respectively.

4. Convertible Debenture

4. Convertible Debenture	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
4. Convertible Debenture	4. Convertible Debenture On March 23, 2015, the Company issued $100,000 convertible debentures. The maturity date is September 23, 2015. The convertible debentures bear interest at a rate of eight-percent (8%) per annum. Until the ninetieth day after the issuance date the Company may pay the principal at a cash redemption premium of 130%, in addition to outstanding interest, without the Holder’s consent; from the 90 th On April 1, 2015, the Company issued a $125,000 convertible redeemable note. The maturity date is March 31, 2016. The convertible debentures bear interest at a rate of eight-percent (8%) per annum. The Convertible price is equal to 58% of lowest trading price of the common stock as reported on the national Quotations Bureau OTCQB exchange which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the twenty prior trading days including the day upon which a Notice of Conversion is received by the company. The Company received money on April 1, 2015. On the October 7, 2015, the Holder elected to convert a $7,500 plus accrued interest $311 into 96,121 shares of the Company’s Common Stock at $0.081258 per share. On June 5, 2015, the Company entered into and closed a securities purchase agreement (the “St. George SPA”) with St. George Investments LLC (“St. George”), pursuant to which the Company issued, sold to St. George a convertible promissory note in the principal amount of $110,000 (the “St. George Note”) for a purchase price of $100,000, and granted to St. George a number of warrants (St. George Warrants”) that are equal to $55,000, divided by the Conversion Price, with an exercise price of $1.00 that have an expiration date which is the last calendar day of the month in which the first anniversary of the Issue Date occurs. The St. George Note is convertible into the Company’s common stock at a conversion price equal to 62% of the lowest closing bid price of the common stock for the twenty trading days prior to conversion. Repayment of the St. George Note is due one year from the date of issuance. The St. George Note accrues interest at the rate of 8% per year, due at maturity. The Company may prepay the St. George Note, upon five days written notice and subject to the optional prepayment amount of 125% multiplied by the then outstanding balance on the St. George Note. On July 22, 2015, the Company entered a securities purchase agreement. The buyer wished to purchase from the Company securities consisting of the Company’s Convertible Debenture due three years from the respective date of issuance, which will be convertible into shares of the Company’s common stock in the aggregate principal amount of up to $335,000, for an aggregate purchase price of up to $301,500. Conversion price is 60% of the lowest closing bid price of Common stock for the 20 trading days immediately preceding the date of conversion of the Debentures. Three Debentures will be issued. “Signing Debenture” is the first of the three Debentures, in the principal amount of $85,000, to be issued by the Company on Signing Closing date. On July 22, 2015 the Company issued “Signing Debenture” for $85,000. The Company received the money on July 24, 2015. “Second Debenture” is the second of three Debentures, in the principal amount $125,000, which is issued by the Company at any time 61 to 100 days following the signing closing date. “Third Debenture” is the third of the three Debentures, in the principal amount of $125,000, to be issued by the Company at any time 61 to 100 days following the Second Debenture issued date. The Compound derivative comprises certain derivative features embedded in the host convertible debenture contracts including the conversion feature and warrants both of which contain anti-dilution protections. These instruments were combined into one compound derivative and bifurcated from the host instrument at fair value. The Company applied the Black-Scholes Merton valuation technique to fair value these derivatives because this technique embodies all of the assumptions necessary to fair value these compound derivative instruments. Since the derivative financial instruments are required to be recorded, both initially, and subsequently, at fair value, there were insufficient proceeds to allocate any amount to the convertible debentures and, accordingly, it has no carrying value on the date of inception. Additionally, proceeds were insufficient to record the fair values of the derivative financial instruments, resulting in initial interest expense of $295,581. It should be noted that the derivative instruments will be adjusted to fair value at each reporting date. The initial fair value of the derivative was $780,125. There was a gain on the fair value derivative of $348,614 and reclassified $12,497 as additional paid in capital on conversion, resulting in the end balance of $467,865.

5. Line of Credit

5. Line of Credit	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
5. Line of Credit	5. Line of Credit On August 7, 2015, The Company issued a Revolving Line of Credit Promissory Note with the principal sum up to $250,000. Revolving line of credit available for a period of 12 months. Interest rate is 1.8% every 30 days. As of September 30, 2015, unpaid principal balance is $10,000.

6. Capital Stock

6. Capital Stock	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
6. Capital Stock	6. Capital Stock Preferred Stock The Company’s capitalization is 50,000,000 shares of preferred stock, with a par value of $0.001 per share, with 0 shares issued and outstanding at September 30, 2015. Common Stock On January 27, 2015, the Company entered stock subscription agreement of 10,000 shares at $0.50 per share with 10,000 warrants to purchase 10,000 shares of common stock with an exercise price of 1.00 per share. These warrants expire 360 days after stock issuance date. On February 2, 2015, the Company entered stock subscription agreement of 12,000 shares at $0.50 per share with 12,000 warrants to purchase 12,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date. On February 3, 2015, the Company entered stock subscription agreement for 21,600 shares at $0.50 per share. On February 18, 2015, the Company entered stock subscription agreement of 50,000 shares at $0.50 per share with 50,000 warrants to purchase 50,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date. On February 9, 2015, the Company entered a consulting agreement whereby the Company issued 15,000 shares, valued at $.75/share or $11,250 for consulting services, on a month to month basis. On February 19, 2015, the Company entered a consulting agreement whereby the Company issued 25,000 shares for consulting services valued at $.70/share or $17,500, on a month to month basis. On February 21, 2015, the Company entered stock subscription agreement of 2,000 shares at $0.50 per share with 2,000 warrants to purchase 2,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date. On February 21, 2015, the Company entered stock subscription agreement of 10,000 shares at $0.50 per share with 10,000 warrants to purchase 10,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date. On February 21, 2015, the Company entered stock subscription agreement of 2,000 shares at $0.50 per share with 2,000 warrants to purchase 2,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date. On February 23, 2015, the Company entered stock subscription agreement of 10,000 shares at $0.50 per share with 10,000 warrants to purchase 10,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date. On February 18, 2015, the Company entered a service agreement whereby the Company issued 15,000 shares for marketing solution and strategy services valued at $.70 per share or $10,500, on a month to month basis. On March 10, 2015, the Company entered stock subscription agreement of 50,000 shares at $0.50 per share with 50,000 warrants to purchase 50,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date. On March 10, 2015, the Company entered stock subscription agreement of 2,000 shares at $0.50 per share with 2,000 warrants to purchase 2,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date. On March 14, 2015, the Company entered an independent contractor agreement whereby the Company issued 100,000 shares for medical services valued at $.82 per share or $82,000. This amount will be amortized over the contract period of one year. On March 14, 2015, the Company entered an independent contractor agreement whereby the Company issued 10,000 shares for medical services valued at $.82 per share or $8,200. This amount will be amortized over the contract period of one year. On April 8, 2015, the Company entered stock subscription agreement of 20,000 shares at $0.50 per share with 50,000 warrants to purchase 50,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date. On April 16, 2015, the Company entered a consulting agreement whereby the Company issued 125,000 shares for product development consulting services valued at $.95/share or $118,625. On April 16, 2015, the Company entered a consulting agreement whereby the Company issued 30,000 shares for consulting services valued at $.95/share or $28,470. On April 22, 2015, the Company entered a consulting agreement whereby the Company will issue 300,000 shares for consulting services, for a period of six months. 150,000 shares will issued within 30 days of the date of agreement and another 150,000 shares will issued on or before the 150th day from the effective date if the agreement has not been terminated. On April 22, 2015, the Company issued 150,000 shares valued at $.85/share or $127,350. On June 13, 2015, the Company entered a consulting agreement whereby the Company issued 15,000 shares for marketing services valued at $.74/share or $11,085. On September 24, 2015, the Company issued 83,292 shares of its common stock at $0.12006 for conversion of convertible debentures of $10,000. Due to a ratchet provision, the warrants issued during 2015 were accounted for as a derivative and fair valued using the Black Scholes valuation model. The initial valuation for warrants was $129,001. There was a gain on the fair value derivative of $161,537, resulting in the ending balance of $16,315. The Company’s capitalization is 300,000,000 shares of common stock, with a par value of $0.001 per share, with 50,896,385 shares issued and outstanding at September 30, 2015. Stock Purchase Warrants The following table summarizes all warrant activity for the year ended December 31, 2014 and nine months ended September 30, 2015: Shares Weighted-Average Exercise Price Per Share Remaining term Intrinsic value Outstanding, December 31, 2014 189,963 2.00 Exercisable at December 31, 2014 189,963 2.00 0.78 year $ 0 Granted 463,858 1.00 Exercised - - Expired (169,963) - Outstanding and Exercisable at September 30, 2015 483,858 1.00 0.40 year $ 0

7. Fair Value Measurements

7. Fair Value Measurements	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
7. Fair Value Measurements	7. Fair Value Measurements On a recurring basis, we measure certain financial assets and liabilities based upon the fair value hierarchy as described in the Company’s significant accounting policies in Note 1. The following table presents information about the Company’s liabilities measured at fair value as of September 30, 2015 and December 31, 2014: Level 1 Level 2 Level 3 Fair Value at September 30, 2015 Liabilities Derivative Liability - $ 467,865 $ 467,865 Level 1 Level 2 Level 3 Fair Value at December 31, 2014 Liabilities Derivative Liability - $ 48,851 - $ 48,851 The fair value changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 2), relate solely to the derivative liability as follows: Amount Balance at December 31, 2014 $ 48,851 New warrant issued with stock/convertible debentures 780,125 Fair value adjustment (348,614) Decrease due to Conversion of convertible debenture (12,497) Balance at September 30, 2015 $ 467,865

8. Related Parties

8. Related Parties	9 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
8. Related Parties	8. Related Parties An affiliate of the Company, the Company’s president, has been funding operations of the Company by making payments directly to third parties or advancing monies to the Company. These amounts bear no interest and are payable on demand. Amounts due to the affiliate at September 30, 2015 and December 31, 2014 are $276,156 and $270,747, respectively. During June 2012, the Company borrowed $125,000 from an affiliate. The loan bears interest at 10% per annum and is unsecured and payable upon demand. The outstanding balance as of September 30, 2015 is $77,401 and accrued interest is $23,845. On August 28, 2014, the Company authorized the purchase of 64,666,619 shares of common stock from affiliate at $0.001 per share and signed an unsecured promissory note for a total of $64,667 to affect the purchase. The loan bears interest at 6% per annum and is unsecured and payable upon demand. The Company has paid $0 towards the loan amount as of September 30, 2015. The outstanding balance as of September 30, 2015 is $64,667 and accrued the interest is $5,360 On August 28, 2014, the Company authorized the purchase of 3,000,000 shares of common stock from shareholder at $0.005 per share and signed a promissory note for a total of $15,000 to affect the purchase. The loan bears interest at 6% per annum and is unsecured and payable upon demand. The Company has paid $0 towards the loan amount as of September 30, 2015. The outstanding balance as of September 30, 2015 is $15,000 and accrued the interest $1,289

9. Significant Agreement

9. Significant Agreement	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
9. Significant Agreement	9. Significant Agreement On or about February 26, 2015, the Company entered into a distribution agreement (“Distribution Agreement”) with Yontem Cosmetics Dis Tic. Ltd. Sti (“Yontem”) a Turkish company; thereby, naming Turkey (the “Territory”) as an exclusive territory for Yontem. The terms of the Distribution Agreement, expects that Yontem will sell a minimum of 1,000 1.7oz units per month during the 1st year, 2,000 1.7oz units per month during the second year of operation and 3,000 units per month in the third year upon the establishment of the company by Yontem. The Distribution Agreement is for an initial period of three years and then the two parties will evaluate the progress of the Distribution Agreement. The Distribution Agreement can then be renewed for an additional five-five year periods. The Distribution Agreement also states that in order to maintain exclusivity on the Territory the quota numbers must be met, and that if they are not met then Yontem will lose exclusivity to the Territory. On or about June 5, 2015, the Company entered into a distribution agreement (“Distribution Agreement”) with RAVL Ltd (“RAVL”) a Ukraine company; thereby, naming Ukraine (the “Territory”) as an exclusive territory for RAVL. The terms of the Distribution Agreement shall be for a period of 5 years to evaluate the progress for renewal for five-five year periods. Quotas will be agreed upon after 1 st On July 1, 2015, The Company entered into a service agreement with Kon-Lin Investors Ltd (“Kon-Lin”). Kon-Lin will provide technical analysis of the Company’s common stock to include analysis of charts, tends, moving average, time, supply and demand. The consideration for the service is $5,000 per month and this agreement will continue on a month to month basis On or about July 19, 2015, the Company entered into a distribution agreement (“Distribution Agreement”) with Houboubati Group Companies (Hounoubati); thereby, naming Saudi Arabia, Qatar, Kuwait and UAE Region (the “Territory”) as an exclusive territory for Houboubati. The terms of the Distribution Agreement shall be for a period of six months to evaluate the progress for renewal period to term of an additional two years. Quotas will be agreed upon after the first six periods. Houboubati is expected to order a minimum of 1,000 units with the completion of the product being properly registered for the sales in the territory.

10. Subsequent Events

10. Subsequent Events	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
10. Subsequent Events	10. Subsequent Events On the October 7, 2015, one of the holders of a convertible debenture elected to convert principal of $7,500 and accrued interest $311 into 96,121 shares of the Company’s Common Stock. On October 13, 2015, the Company issued a convertible promissory note. The principal sum of the note is up to $500,000. The consideration is $450,000 payable by wire (there exists a $50,000 original issue discount). The maturity date is two years from the effective date of each payment and is the date upon which principal sum of the note and any unpaid interest and other fee shall be due and payable. The convertible promissory note bears interest at a rate of twelve-percent (12%) per annum. The Conversion Price is 62% of the lowest trade price in the 25 trading days previous to the conversion. The investor has conversion right at any time after the Effective date. The Company may repay a payment at any time on or before 90 days from effective date in an amount equal to 110% of principal plus all accrued and unpaid interest, OID and other fee, or any time after 90 days of Effective date and before 179 days in an amount equal 140% of principal plus all accrued and unpaid interest, OID and other fee. The Company may not repay any payment of considerations after 179 days of Effective date. On the October 14, 2015, one of the holders of a convertible debenture elected to convert principal of$20,000 into 237,925 shares of the Company’s Common Stock. On October 20, 2015, the Company designates 40,000 shares as Series A Preferred stock and 10,000 shares as Series B Preferred Stock. Series A Preferred stock shall not be entitled to receive dividends. Series A Preferred Stock can convert to common stock in a conversion rate 1 to 1,000 (one share of Series A convertible preferred stock can convert to One thousand shares of Common stock) with no consideration. Series B Preferred stock shall not be entitled to receive dividends. Series B Preferred Stock can convert to common stock in a conversion rate 1 to 1,000 (one share of Series B convertible preferred stock can convert to One thousand shares of Common stock) with no consideration. If the Series B Preferred stock Holder entitle to convert any portion of its Series B Convertible Preferred Stock that would result in the beneficial ownership by Holder and its affiliates of more than 9.99% of outstanding shares of common stock. The number of shares of Common Stock to be issued shall be determined by multiplying the Convertible rate by the amount to be converted. Series A and Series B Preferred Stock have full voting right as Common stock holders. Each Series A or Series B Preferred Stock vote right is equal One Thousand vote per share on Common stock. On the October 19, 2015, one of the holders of a convertible debenture elected to convert principal of $7,500 and accrued interest $330 into 96,364 shares of the Company’s Common Stock. On the October 27, 2015, one of the holders of a convertible debenture elected to convert principal of $6,000 and accrued interest $275 into 98,262 shares of the Company’s Common Stock. On the November 3, 2015, one of the holders of a convertible debenture elected to convert principal of$20,000 into 416,666 shares of the Company’s Common Stock. Pursuant to Accounting Standards Codification 855-10, the Company has evaluated all events or transactions that have occurred from September 30, 2015 through the filing with the SEC.

1. Nature of Operations and B16

1. Nature of Operations and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations Rejuvel Bio-Sciences, Inc. (f/k/a Technology Applications International Corporation) was incorporated on October 14, 2009 under the laws of Florida. Rejuvel Int’l, Inc. and NueEarth, Inc., Rejuvel Bio-Sciences, Inc.’s wholly owned subsidiaries and Rejuvel Bio-Sciences, Inc., collectively, are referred to here-in as the “Company”. The Company is engaged in developing market entry technology products and services into early and mainstream technology products and services. Through our subsidiaries, we are focused on developing and manufacturing a line of technologically advanced skin care products and providing environmental management solutions that use electron particle accelerator technology.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Rejuvel Bio-Sciences, Inc., and its wholly owned subsidiaries, Rejuvel Int’l, Inc. and NueEarth, Inc. All significant inter-company accounts and transactions have been eliminated in consolidation.
Basis of Presentation and Going Concern Considerations	Basis of Presentation and Going Concern Considerations The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2015 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2015. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. The accompanying financial statements have been presented on the basis that it is a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs. The Company’s ability to continue as a going concern is highly dependent upon management’s ability to increase near-term operating cash flows and obtain additional working capital through the issuance of debt and or equity. If the Company is unable to obtain adequate capital, it could be forced to cease operations. These condensed consolidated financial statements present the financial condition, and results of operations and cash flows of the operating companies.
Business Risk	Business Risk Since its inception, the Company has been dependent upon the receipt of capital investment to fund its operating activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plans will be successfully executed. The Company’s ability to execute its business plans is dependent on its ability to obtain additional debt and equity financing and achieving a profitable level of operations. There can be no assurance that sufficient financing will be obtained or that we will achieve a profitable level of operations.
Basic and Diluted Net Loss per Share	Basic and Diluted Net Loss per Share The Company computes loss per share in accordance with “ASC-260”, “Earnings per Share” which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. The Company has potential dilutive instruments during the current three month period as there is net income; therefore there is potentially a dilutive share amount of 106,245,144. The Company does not have potential dilutive instruments during the nine month period and comparable periods as there are net losses, and accordingly basic loss and diluted loss per share are the same.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position or results of operations upon adoption.

2. Inventories (Tables)

2. Inventories (Tables)	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Inventories	September 30, 2015 December 31, 2014 Raw materials $ - $ - Work-in-process 19,904 - Finished goods 14,922 4,831 Total Inventories $ 34,826 $ 4,831

3. Machinery and Equipment (Tab

3. Machinery and Equipment (Tables)	9 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Machinery and equipment	Estimated Useful Lives September 30, 2015 December 31, 2014 Computer Equipment 3 Years $ 3,796 $ 5,980 Machinery and equipment 5 Years 33,192 29,935 Furniture and fixtures 7 Years 13,000 14,073 Accumulated depreciation (22,347) (17,896) $ 27,641 $ 32,092

6. Capital Stock (Tables)

6. Capital Stock (Tables)	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Warrant Activity	Shares Weighted-Average Exercise Price Per Share Remaining term Intrinsic value Outstanding, December 31, 2014 189,963 2.00 Exercisable at December 31, 2014 189,963 2.00 0.78 year $ 0 Granted 463,858 1.00 Exercised - - Expired (169,963) - Outstanding and Exercisable at September 30, 2015 483,858 1.00 0.40 year $ 0

7. Fair Value Measurements (Tab

7. Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Derivative Liabilities	Level 1 Level 2 Level 3 Fair Value at September 30, 2015 Liabilities Derivative Liability - $ 467,865 $ 467,865 Level 1 Level 2 Level 3 Fair Value at December 31, 2014 Liabilities Derivative Liability - $ 48,851 - $ 48,851
Derivative Liability Fair Value Adjustment	Amount Balance at December 31, 2014 $ 48,851 New warrant issued with stock/convertible debentures 780,125 Fair value adjustment (348,614) Decrease due to Conversion of convertible debenture (12,497) Balance at September 30, 2015 $ 467,865

2. Inventories (Details)

2. Inventories (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 0	$ 0
Work-in-process	19,904	0
Finished goods	14,922	4,831
Total Inventories	$ 34,826	$ 4,831

2. Inventories (Details Narrati

2. Inventories (Details Narrative) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Reserves for inventory	$ 0	$ 0

3. Machinery and Equipment (Det

3. Machinery and Equipment (Details) - USD ($)	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Computer Equipment	$ 3,796	$ 5,980
Machinery and equipment	33,192	29,935
Furniture and fixtures	13,000	14,073
Accumulated depreciation	(22,347)	(17,896)
Machinery and equipment, net	$ 27,641	$ 32,092
Computer Equipment
Estimated useful lives, min	3 years
Machinery and Equipment
Estimated useful lives, min	5 years
Estimated useful lives, max	7 years
Furniture and Fixtures
Estimated useful lives, min	7 years

3. Machinery and Equipment (D24

3. Machinery and Equipment (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 1,499	$ 1,483	$ 4,451	$ 3,964

4. Convertible Debenture (Detai

4. Convertible Debenture (Details Narrative) - USD ($)	Nov. 03, 2015	Oct. 27, 2015	Oct. 19, 2015	Oct. 14, 2015	Oct. 12, 2015	Oct. 07, 2015	Sep. 24, 2015	Jul. 22, 2015	Mar. 23, 2015	Sep. 30, 2015	Oct. 13, 2015	Jun. 05, 2015	Apr. 08, 2015	Apr. 01, 2015	Mar. 10, 2015	Feb. 23, 2015	Feb. 21, 2015	Feb. 18, 2015	Feb. 02, 2015	Jan. 27, 2015
Notes to Financial Statements
Purchase price of promissory note								$ 301,500				$ 100,000
Convertible debenture issued								$ 335,000	$ 100,000		$ 500,000	$ 110,000		$ 125,000
Interest rate of convertible debenture, per annum									8.00%		12.00%	8.00%		8.00%
Warrants issued with convertible security, value												$ 55,000
Exercise price of warrants issued in convertible debenture issuance												$ 1	$ 1		$ 1	$ 1	$ 1	$ 1	$ 1	$ 1
Prepayment percent to prepay convertible note												125.00%
Conversion price of warrants equal to percent of lowest closing bid price of common stock for twenty days								60.00%				62.00%		58.00%
Maturity date of convertible debenture									90 days
Ninety day cash redemption percent									130.00%
Maturity day cash redemption percent									135.00%
Late cash redemption percent									150.00%
Percent discount on trading price to convert loan to common stock									40.00%		62.00%
Number of days to calculate average trading price									20 days
Interest expense										$ 295,581
Initial fair value of derivative												$ 780,125
Gain on the fair value derivative										467,865
Debt conversion to common stock rate	$ .048			$ .08406		$ .081258	$ 0.12006
Gain (loss) on derivative valuation										(348,614)
Additional paid in capital on conversion										$ 12,497
Amount of debt converted from debentures	$ 20,000	$ 6,275	$ 7,830	$ 20,000		$ 7,811	$ 10,000
Shares of common stock issued from conversion of debentures	416,666	98,262	96,364	237,925		96,121	83,292
Duration of promissory note					2 years			3 years

5. Line of Credit (Details Narr

5. Line of Credit (Details Narrative) - USD ($)	Aug. 07, 2015	Sep. 30, 2015	Dec. 31, 2014
Notes to Financial Statements
Principal amount of revolving line of credit	$ 250,000
Period of line of credit	12 months
Interest rate of line of credit	1.80%
Interest calculation period of line of credit	30 days
Unpaid principal balance of line of credit		$ 10,000	$ 0

6. Capital Stock (Details)

6. Capital Stock (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Outstanding
Number of Warrant Shares, instant		189,963
Weighted Average Exercise Price, instant		$ 2
Exercisable
Number of Warrant Shares, instant	483,858	189,963
Weighted Average Exercise Price, instant	$ 1	$ 2
Remaining term, duration	5 months	9 months
Intrinsic Value, instant	$ 0	$ 0
Granted
Number of Warrant Shares, duration		463,858
Weighted Average Exercise Price, duration		$ 1
Exercised
Number of Warrant Shares, duration		0
Weighted Average Exercise Price, duration		$ 0
Expired
Number of Warrant Shares, duration		(169,963)
Weighted Average Exercise Price, duration		$ 0

6. Capital Stock (Details Narra

6. Capital Stock (Details Narrative) - USD ($)	Apr. 08, 2015	Mar. 14, 2015	Sep. 30, 2015	Jun. 13, 2015	Jun. 05, 2015	Apr. 22, 2015	Apr. 16, 2015	Mar. 10, 2015	Feb. 23, 2015	Feb. 21, 2015	Feb. 19, 2015	Feb. 18, 2015	Feb. 03, 2015	Feb. 02, 2015	Jan. 27, 2015
Notes to Financial Statements
Common stock issued for cash, shares	20,000							52,000	10,000	14,000		50,000	216,000	12,000	10,000
Common stock issued for services, shares		110,000		15,000		150,000	155,000				25,000	15,000
Common stock issued for services, value				$ 11,085			$ 147,095
Common stock issued for services, price per share				$ .74		$ .85	$ .96
Common stock to be issued for future services						150,000
Common stock price per share	$ 0.50							$ .50	$ 0.50	$ .50		$ 0.50	$ 0.50		$ .50
Shares issued for medical services, shares		110,000
Shares issued for medical service, value		$ 90,200
Amorization period of shares issued for medical services		1 year
Initial valuation of warrants			$ 129,739
Gain on the fair value of derivative			161,537
Warrant valuation from Black Sholes and ratchet provision			$ 16,315
Warrant expiration period	1 year
Warrants included in stock issuance	50,000							52,000	10,000	14,000		50,000		12,000	10,000
Shares underlying warrants in stock issuance	50,000							52,000	10,000	14,000		50,000		12,000	10,000
Exercise price of warrants in stock issuance	$ 1				$ 1			$ 1	$ 1	$ 1		$ 1		$ 1	$ 1

7. Fair Value Measurements - De

7. Fair Value Measurements - Derivative Liabilities (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Derivative liability	$ 467,865	$ 48,851
Level 1
Derivative liability	0	0
Level 2
Derivative liability	467,865	48,851
Level 3
Derivative liability	0	0
Fair Value
Derivative liability	$ 467,865	$ 48,851

8. Related Parties (Details Nar

8. Related Parties (Details Narrative) - USD ($)	1 Months Ended
	Jun. 30, 2012	Sep. 30, 2015	Dec. 31, 2014	Aug. 28, 2014
Affiliate advances		$ 276,156	$ 270,747
Loan from affiliate	$ 125,000
Interest rate on loan from affiliate	10.00%
Repayments on loan from affiliate	$ 0
Oustanding balance on loan from affiliate		77,401
Accrued interest		$ 23,845
Purchase Of Common Stock From An Affiliate
Common stock bought from affiliate, shares				64,666,619
Common stock bought from affiliate, price per share				$ .001
Promissory note issued for common stock bought from affiliate				$ 64,667
Interest rate of promissory note issued for common stock bought from affiliate				6.00%
Amount repaid on promissory note issued for common stock bought from affiliate				$ 0
Outstanding balance on promissory note issued for common stock bought from affiliate				64,667
Accrued interest on promissory note issued for common stock bought from affiliate				$ 5,360
Purchase Of Common Stock From Stockholder
Common stock bought from shareholder, shares				3,000,000
Common stock bought from shareholder, price per share				$ .005
Promissory note issued for common stock bought from shareholder				$ 15,000
Interest rate of promissory note issued for common stock bought from shareholder				6.00%
Amount repaid on promissory note issued for common stock bought from shareholder				$ 0
Outstanding balance on promissory note issued for common stock bought from shareholder				15,000
Accrued interest on promissory note issued for common stock bought from shareholder				$ 1,289

9. Significant Agreement (Detai

9. Significant Agreement (Details Narrative)	Jun. 05, 2015	Feb. 26, 2015	Sep. 30, 2015USD ($)
Distribution agreement with Yontem
Skin cream units agreed to sell per month, first year minimum		1,000
Skin cream units agreed to sell per month, second year minimum		2,000
Skin cream units agreed to sell per month, third year minimum		3,000
Distibution Agreement duration		3 years	6 months
Distribution agreement with RAVL
Skin cream units agreed to sell per month, first year minimum	192
Distibution Agreement duration	5 years
Service Agreement due to Kon-Lin per month			$ 5,000
Duration of distribution agreement		3 years	6 months
Expected minimum order of units			1,000

10. Subsequent Events (Details

10. Subsequent Events (Details Narrative) - USD ($)	Nov. 03, 2015	Oct. 27, 2015	Oct. 19, 2015	Oct. 14, 2015	Oct. 12, 2015	Oct. 07, 2015	Sep. 24, 2015	Jul. 22, 2015	Oct. 20, 2015	Oct. 13, 2015	Jun. 05, 2015	Apr. 08, 2015	Apr. 01, 2015	Mar. 23, 2015	Mar. 10, 2015	Feb. 23, 2015	Feb. 21, 2015	Feb. 18, 2015	Feb. 03, 2015	Jan. 27, 2015
Amount of debt converted from debentures	$ 20,000	$ 6,275	$ 7,830	$ 20,000		$ 7,811	$ 10,000
Shares of common stock issued from conversion of debentures	416,666	98,262	96,364	237,925		96,121	83,292
Debt conversion to common stock rate	$ .048			$ .08406		$ .081258	$ 0.12006
Series A Preferred Stock designated									40,000
Series B Preferred Stock designated									10,000
Common stock issued for cash, price per share												$ 0.50			$ .50	$ 0.50	$ .50	$ 0.50	$ 0.50	$ .50
Convertible debenture issued								$ 335,000		$ 500,000	$ 110,000		$ 125,000	$ 100,000
Convertible debenture issue discount										$ 50,000
Duration of promissory note					2 years			3 years
Interest rate of convertible debenture, per annum										12.00%	8.00%		8.00%	8.00%
Percent discount on trading price to convert loan to common stock										62.00%				40.00%
Series A Preferred Stock
Preferred Stock share convertible to common stock, amount									1,000
Series B Preferred Stock
Preferred Stock share convertible to common stock, amount									1,000